Williams Cancer Institute

SYNC-T Technology: Advancements in Cancer Therapy

Syncromune® Inc., a leading biopharmaceutical company, has unveiled promising outcomes from its Phase 1 trial of SYNC-T™ therapy at the American Association for Cancer Research (AACR) Annual Meeting 2024. SYNC-T, a cutting-edge personalized treatment tailored for solid tumor cancers, demonstrated an impressive overall response rate (ORR) of 85% in patients with metastatic castrate-resistant prostate cancer (mCRPC).

Dr. James Armitage, Chairman of Syncromune’s Scientific Advisory Board, hailed the results as groundbreaking, highlighting SYNC-T’s potential as a game-changing therapy for mCRPC. The therapy, which combines partial tumor lysis with intratumoral immunotherapy, aims to activate the immune system and enhance its ability to target cancer cells throughout the body.

SYNC-T’s innovative approach involves freezing a portion of the tumor to release cancer-specific signals and then administering a fixed-dose multi-target drug, SV-102, directly into the tumor site. This strategy not only stimulates the immune system but also mitigates immune suppression mechanisms, offering a new ray of hope for patients with mCRPC.

The Phase 1 trial enrolled 15 mCRPC subjects, most of whom had diffuse bone metastases and had undergone prior therapies without success. Remarkably, SYNC-T therapy yielded an 85% ORR, with five complete responses (CRs) and six partial responses (PRs) among the evaluated subjects. Importantly, the treatment exhibited minimal side effects and no significant safety concerns.

Dr. George Prendergast, President and CEO of the Lankenau Institute for Medical Research, emphasized the significance of SYNC-T’s clinical response in mCRPC, noting its potential to revolutionize treatment outcomes in a disease with limited therapeutic options and high mortality rates.

These promising results underscore the importance of ongoing clinical trials to further validate SYNC-T Therapy’s efficacy and safety profile. As Syncromune continues to advance its groundbreaking research, SYNC-T emerges as a potential first-in-class therapy for patients with mCRPC and other solid tumors.


Reference: FORT LAUDERDALE, Fla., April 08, 2024 (GLOBE NEWSWIRE) – Syncromune® Inc. Presents Positive Results from SYNC-T™ SV-102 Phase 1 Trial at AACR Annual Meeting 2024. https://www.biospace.com/article/syncromune-inc-presents-positive-results-from-sync-t-sv-102-phase-1-trial-at-aacr-annual-meeting-2024

Related Posts

Blog 21 de mayo de 2024
Blog 20 de mayo de 2024
Blog 06 de mayo de 2024
1 2 3 111